Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Response Rates in CHC Genotype 1 with Insulin Resistance
NCT00493805Phase 4Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2007
- Primary completion
- Oct 2009
- Modality
- Polymer-based Nanoparticles, Orthosteric Ligands, Cytokines & Interferons
01
Overview
Phase 4, randomised, open-label trial of peginterferon alfa-2b and ribavirin in hepatitis C (HCV) (2 arms), sponsored by Merck & Co. Primary endpoint: Early Virological Response at 12 weeks. Started Apr 2007; status: terminated.
02
Drugs
peginterferon alfa-2bribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00493805.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00493805.